Mineralocorticoid receptor blockade in chronic kidney disease. - Wikidata - awgldk - TriplyDB

Mineralocorticoid receptor blockade in chronic kidney disease.

Mineralocorticoid receptor blockade in chronic kidney disease.

http://www.wikidata.org/entity/Q37861583

about

Mineralocorticoid receptor blockade in chronic kidney disease Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.Targeting nuclear receptors with marine natural products.Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.An update of the blockade of the renin angiotensin aldosterone system in clinical practice.

P2860

Q26864370-D3C203D6-5C24-4834-9EA6-2A88E495493B Q27333455-7BCA7A2C-7778-4A35-A6DC-D81F53B97EB5 Q37580301-13E6E9F4-679F-410A-B800-972B2CE85AD8 Q37621100-823BE45C-D62C-40F1-8BF3-63BA77B0CEE5 Q37976974-3C37B13D-BAB7-440B-8BAA-A37E0E061BA4 Q38052452-F753F621-D6C6-4502-9E95-DCCEF1ECE432 Q38590227-9777334C-3432-4062-A6A0-DC2E5AFA75E9

P2860

Mineralocorticoid receptor blockade in chronic kidney disease.

http://www.wikidata.org/entity/Q37861583

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Mineralocorticoid receptor blockade in chronic kidney disease.

@en

Mineralocorticoid receptor blockade in chronic kidney disease.

@nl

type

label

Mineralocorticoid receptor blockade in chronic kidney disease.

@en

Mineralocorticoid receptor blockade in chronic kidney disease.

@nl

prefLabel

Mineralocorticoid receptor blockade in chronic kidney disease.

@en

Mineralocorticoid receptor blockade in chronic kidney disease.

@nl

P1433

Q37861583-0C14E9D2-8876-4B1C-9F9C-044A49BBFBC6

P1476

Q37861583-D9446B4F-B8C9-4F2D-905A-6CE60DB7DFBF

P2093

Q37861583-823342AC-E7A9-4F77-8D92-3B25B90DB925

Q37861583-8EC5905F-2063-4ADB-BC58-093D899DB040

Q37861583-E75CC556-B34E-4178-BEC9-DBE8CAEE6B8D

P2860

Q37861583-0211446E-23D8-44D1-B191-E2D8CA133935

Q37861583-0457EE3F-85E0-4C14-9A9C-840383C77598

Q37861583-048107FB-CF92-4740-B7DB-7D5863BB60F1

Q37861583-09023539-1B99-4BCC-ABD4-DAC93B1D9E3C

Q37861583-1160E569-F382-489B-A2DD-F835F9B6EAC2

Q37861583-1B10EA0B-9187-4863-A19C-E3656F472D12

Q37861583-1D4A16E4-910D-44DE-BD4E-B3F68C0239FF

Q37861583-1DEA3388-A516-4002-A09C-F0B23E77A1B8

Q37861583-2A8B843D-10E2-42D3-95FA-6460F8B73B8C

Q37861583-2CE6D9FC-4FF9-45EE-9C78-0086B62407BC

P2888

Q37861583-102B4429-B5AC-456A-9213-E7FF96B9A9C3

P304

Q37861583-BA56FF08-005F-4B2E-B404-E03996B7152F

P31

Q37861583-4689333D-B4DF-4679-9BAB-338D3B29B61D

P356

Q37861583-E4EC5317-54C0-47C5-9DAA-5D2516E88F3A

P433

Q37861583-C3DC03FC-3703-4596-BB69-2D58252192F5

P478

Q37861583-6D60F44A-7CCF-4383-BBA7-F340E77EC153

P577

Q37861583-907C1505-AC78-46A9-8A5E-A69BCEE4985C

P698

Q37861583-88777FC1-0DF6-442E-9CD9-424B27C125B6

P356

S11906-011-0202-2

P1433

Current Hypertension Reports

P1476

Mineralocorticoid receptor blockade in chronic kidney disease.

@en

P2093

Andrew S Bomback

http://www.w3.org/2001/XMLSchema#string

Matthew J Volk

http://www.w3.org/2001/XMLSchema#string

Philip J Klemmer

http://www.w3.org/2001/XMLSchema#string

P2860

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Molecular mechanisms of human hypertension.

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.

Aldosterone: role in the cardiometabolic syndrome and resistant hypertension

Disordered aldosterone-volume relationship in end-stage kidney disease.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome.

Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status.

P2888

s11906-011-0202-2

P304

282-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11906-011-0202-2

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21465140

http://www.w3.org/2001/XMLSchema#string